Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439387 | PMC |
| http://dx.doi.org/10.1016/j.rpth.2023.100201 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dabigatran-reversal failure using standard dose of idarucizumab: a systematic review and meta-analysis of cases.
Res Pract Thromb Haemost
July 2023
Hematology Department, Assistance Publique Hôpitaux de Paris, Centre-Université de Paris, Paris, France.
Left atrial appendage thrombus on full-dose dabigatran treatment: a case report.
Eur Heart J Case Rep
June 2020
Division of Cardiology and Coronary Care Unit, AORN Cardarelli, Via Antonio Cardarelli 9, 80128 Naples, Italy.
Background: Dabigatran is a direct competitive thrombin inhibitor approved for stroke prevention in non-valvular atrial fibrillation. At full-dose, dabigatran showed similar rates of bleedings and higher efficacy compared to warfarin.
Case Summary: We report a case of acute ischaemic stroke in a patient treated with dabigatran 150 mg b.
Idarucizumab for dabigatran reversal in daily clinical practice: A case series.
Eur J Anaesthesiol
October 2020
From the Department of Vascular Diseases, University Medical Centre Ljubljana, Ljubljana (NV, AM, MB-M), Department of Plastic and Reconstructive Surgery, University Medical Centre Maribor, Maribor (MG), Department of Anaesthesiology and Reanimation, Trbovlje General Hospital, Trbovlje (KKU), Department of Anaesthesiology, Celje General Hospital, Celje (UŽ), Clinical Department of Anaesthesiology and Intensive Therapy, University Medical Centre Ljubljana (PG, AS), Division of Neurology, University Medical Centre Ljubljana, Ljubljana (SF), Department of Cardiology and Angiology, University Medical Centre Maribor, Maribor (VN), General Hospital, Dr. Franca Derganca Nova Gorica, Šempeter pri Gorici (ND) and Department of Neurology, Celje General Hospital, Celje, Slovenia (IEK).
Background: Real-life experience with idarucizumab, which reverses the anticoagulant effect of dabigatran, is currently limited.
Objective: To evaluate efficacy and safety of the clinical use of idarucizumab after its availability in Slovenia.
Methods: We analysed consecutive cases treated with idarucizumab in Slovenia from January to October 2016.
The (Fab)ulous Destiny of Idarucizumab: Highlighting Its Interference with Urine Protein Immunofixation.
TH Open
July 2019
Laboratoire d'Hématologie, Hôpital Bichat-Claude Bernard, AP-HP, Paris, France.
Idarucizumab is a humanized antigen binding fragment (Fab) of a recombinant anti-dabigatran monoclonal antibody (IgG1-kappa) that allows rapid and sustained reversal of dabigatran-induced anticoagulation in case of bleeding or urgent surgery. Herein, we report a very unusual case of dabigatran reversal by idarucizumab in a 79-year-old woman with acute kidney failure admitted to a hospital in a context of hemoptysis. Three repeated injections were necessary because of massive dabigatran overdose and high rebounds of dabigatran plasma concentration.
View Article and Find Full Text PDFWhole Blood Point-of-Care Testing for Incomplete Reversal With Idarucizumab in Supratherapeutic Dabigatran.
Anesth Analg
February 2020
From the Department of Anesthesiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Background: Incomplete reversal with a recommended 5-g dose of idarucizumab has been reported in patients with excessively high dabigatran concentrations. A timely detection of reversal failure after idarucizumab using whole blood (WB) coagulation testing is clinically useful. The aims of this study were to determine residual dabigatran activity after idarucizumab on thrombin generation (TG) using in vitro supratherapeutic dabigatran models and to compare 4 WB point-of-care tests (activated partial thromboplastin time [aPTT], prothrombin time [PT], and 2 thromboelastometry tests) with the TG results.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!